compounding semaglutide news today FDA Warns on Certain Forms of Compounded Patients Cut Off From Cheaper

Sattar N, Verma S, Sourij H, Wilson J, Stefanski A, Zhang X, Griffin R (2024) Inflammatory biomarkers in people treated with tirzepatide living with overweight or obesity, without and with T2D: a post-hoc analysis from SURMOUNT-1 and SURMOUNT-2

March 19, 2026: Eli Lilly announced TRANSCEND-T2D-1 topline results in adults with type 2 diabetes

Beta cells begin to show signs of stress, and their ability to increase insulin production reaches limits

(Source: Medicare.gov) Two Important Catches in the Bridge Program First, Bridge Program payments do not count toward True Out-of-Pocket (TrOOP) costs , so they dont help beneficiaries reach the catastrophic coverage threshold

Yes, switching is straightforward since its the same medication